Upgrade to SI Premium - Free Trial

Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c, Raises FY Guidance

November 5, 2019 4:22 PM
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.10, $0.51 better than the analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Earnings Guidance

Next Articles